Generic entry is inevitable. Process patents are how you make it expensive.
Most biotech and pharma leaders understand the headline risk: once a product’s composition-of-matter patent expires, generics move in—often faster than management expects and w…
Biotech IPOs can look like rocket fuel—until the patent due diligence catches fire.
If you’re an investor, founder, or advisor, you already know the headline risks: clinical timelines, trial design, manufacturing scale-up, reimbursement. But there’s a …
Don’t Get Burned: 3 Critical Patent Due Diligence Steps Before Investing in Biotech IPOs Read Post »
Most biosimilar entry models fail for the same reason: they assume the market behaves like a spreadsheet.
Here’s the uncomfortable truth: the “entry window” isn’t a date on a calendar—it’s a moving target shaped by patent thickets, regulatory timelines…
5 Costly Mistakes Companies Make When Modeling Biosimilar Entry Windows Read Post »
Most teams don’t lose because their science is weak. They lose because they didn’t know what the patent landscape was telling them.
In generic and biosimilar development, the “go/no-go” decision is often treated like a spreadsheet exercise: estimate ti…
Designing Around the Moat: Why Secondary Formulation Patents Are the New Battleground for Generic Developers
Generic drug development has always been a game of precision—timelines, regulatory strategy, and patent analytics all matter. But in today’s pa…
Designing Around the Moat: A Generic Developer’s Guide to Secondary Formulation Patents Read Post »
Pharma doesn’t just “own” a drug patent—it often extends control over time.
That’s the core tension behind the industry’s playbook for maximizing value from patent term extensions and secondary patents. In a world where blockbuster revenue is measured …
Your pharmaceutical portfolio may have a time bomb in it—and patent expiration data is the fuse.
If you’re a business leader in pharma, you already know the headline risk: patents expire, generics arrive, margins compress, and growth plans get rewritte…
The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/
DrugChatter: Are there any dangers in using lipitor alongside salt substitutes? Read Post »
Big Pharma loves a good wall.
Not the kind you can scale with grit and a ladder—but the kind built from patents, procedural delays, and “trust us” narratives. In the pharmaceutical world, IP strategy can feel like a fortress: opaque, expensive to chall…
Crack the Patent Wall: How Hard Data Beats Big Pharma’s IP Strategy Every Time Read Post »
Brands Don’t Launch “Competition” by Accident—They Do It to Control the Next Phase of the Market
There’s a quiet strategy playing out across pharma that most investors only notice after the damage is done: the authorized generic.
On the surface, it loo…
Get new actionable insights and updates from BiotechBlog
